Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis

References

• Kaminski N, Achiron A. Can blood gene expression predict which patients with multiple sclerosis will respond to interferon?. PLoS Med. 2005; 2:e33.
   Google Scholar
• Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, Hall D, Baier M, Feichter J, Ramanathan M. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol. 2003; 171:2694–2702.
   PubMed Web of Science ®Google Scholar
• Koike F, Satoh J, Miyake S, Yamamoto T, Kawai M, Kikuchi S, Nomura K, Yokoyama K, Ota K, Kanda T, Fukazawa T, Yamamura T. Microarray analysis identifies interferon beta-regulated genes in multiple sclerosis. J Neuroimmunol. 2003; 139:109–118.
   PubMed Web of Science ®Google Scholar
• Satoh J, Nanri Y, Tabunoki H, Yamamura T. Microarray analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFNbeta-responsive genes in peripheral blood lymphocytes in vitro: an implication for IFNbeta-related adverse effects in multiple sclerosis. BMC Neurol. 2006; 6:18.
   PubMed Web of Science ®Google Scholar
• Annibali V, Di Giovanni S, Cannoni S, Giugni E, Bomprezzi R, Mattei C, Elkahloun A, Coccia EM, Alfò M, Orzi F, Ristori G, Salvetti M. Gene expression profiles reveal homeostatic dynamics during interferon-therapy in multiple sclerosis. Autoimmunity. 2007; 40:16–22.
   PubMed Web of Science ®Google Scholar
• Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci. 2007; 258:52–59.
   PubMed Web of Science ®Google Scholar
• Hilpert J, Beekman JM, Schwenke S, Kowal K, Bauer D, Lampe J, Sandbrink R, Heubach JF, Stüzebecher S, Reischl J. Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers. J Neuroimmunol. 2008; 199:115–125.
   Google Scholar
• van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J J, van der Pouw Kraan TC, Polman CH, Verweij CL. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One. 2008; 3:e1927.
   Google Scholar
• Sellebjerg F, Datta P, Larsen J, Rieneck K, Alsing I, Oturai A, Svejgaard A, Soelberg Sørensen P, Ryder LP. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler. 2008; 14:615–621.
   Google Scholar
• Reder AT, Velichko S, Yamaguchi KD, Hamamcioglu K, Ku K, Beekman J, Wagner TC, Perez HD, Salamon H, Croze E. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression. J Interferon Cytokine Res. 2008; 28:317–331.
   PubMedGoogle Scholar
• Rani MR, Shrock J, Appachi S, Rudick RA, Williams BR, Ransohoff RM. Novel interferon-beta-induced gene expression in peripheral blood cells. J Leukoc Biol. 2007; 82:1353–1360.
   Google Scholar
• Muraro PA, Liberati L, Bonanni L, Pantalone A, Caporale CM, Iarlori C, De Luca G, Farina D, Lugaresi A, Gambi D. Decreased integrin gene expression in patients with MS responding to interferon-beta treatment. J Neuroimmunol. 2004; 150:123–131.
   PubMed Web of Science ®Google Scholar
• Baranzini SE, Mousavi P, Rio J, Caillier SJ, Stillman A, Villoslada P, Wyatt MM, Comabella M, Greller LD, Somogyi R, Montalban X, Oksenberg JR. Transcription-based prediction of response to IFNb using supervised computational methods. PLoS Biol. 2005; 3:e2.
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Bhasi K, Badgett D, Tamaño-Blanco M, Minhas M, Feichter J, Patrick K, Munschauer F, Bakshi R, Ramanathan M. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol. 2008; 205:113–125.
   Google Scholar
• Bertolotto A, Gilli F, Sala A, Capobianco M, Malucchi S, Milano E, Melis F, Marnetto F, Lindberg RL, Bottero R, Di Sapio A, Giordana MT. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients. Neurology. 2003; 60:634–639.
   PubMed Web of Science ®Google Scholar
• Malucchi S, Gilli F, Caldano M, Marnetto F, Valentino P, Granieri L, Sala A, Capobianco M, Bertolotto A. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology. 2008; 70:1119–1127.
   PubMed Web of Science ®Google Scholar
• Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, Frank JA, Staudt L, Martin R, McFarland HF. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain. 2003; 126 6: 1419–1429.
   Google Scholar
• Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol. 2004; 56 4: 548–555.
   PubMed Web of Science ®Google Scholar
• Saha S, Rangarajan PN. Common host genes are activated in mouse brain by Japanese encephalitis and rabies viruses. J Gen Virol. 2003; 84:1729–1735.
   PubMed Web of Science ®Google Scholar
• Chin KC, Cresswell P. Viperin (cig5), an IFN-inducible antiviral protein directly induced by human cytomegalovirus. Proc Natl Acad Sci USA. 2001; 98:15125–15130.
   PubMed Web of Science ®Google Scholar
• Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, Loo YM, Gale MJr, Akira S, Yonehara S, Kato A, FujitaT. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol. 2005; 175:2851–2858.
   PubMed Web of Science ®Google Scholar
• Itsui Y, Sakamoto N, Kurosaki M, Kanazawa N, Tanabe Y, Koyama T, Takeda Y, Nakagawa M, Kakinuma S, Sekine Y, Maekawa S, Enomoto N, Watanabe M. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. J Viral Hepat. 2006; 13:690–700.
   Google Scholar
• Samuel MA, Whitby K, Keller BC, Marri A, Barchet W, Williams BR, Silverman RH, Gale MJr, Diamond MS. PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol. 2006; 80:7009–7019.
   PubMed Web of Science ®Google Scholar
• Saha S, Sugumar P, Bhandari P, Rangarajan PN. Identification of Japanese encephalitis virus-inducible genes in mouse brain and characterization of GARG39/IFIT2 as a microtubule-associated protein. J Gen Virol. 2006; 87:3285–3289.
   Google Scholar
• Wacher C, Müller M, Hofer MJ, Getts DR, Zabaras R, Ousman SS, Terenzi F, Sen GC, King NJ, Campbell IL. Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses. J Virol. 2007; 81:860–871.
   PubMed Web of Science ®Google Scholar
• Hallen LC, Burki Y, Ebeling M, Broger C, Siegrist F, Oroszlan-Szovik K, Bohrmann B, Certa U, Foser S. Antiproliferative activity of the human IFN-alpha-inducible protein IFI44. J Interferon Cytokine Res. 2007; 27:675–680.
   Google Scholar
• Malakhova OA, Zhang DE. ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J Biol Chem. 2008; 283:8783–8787.
   PubMedGoogle Scholar
• Peel AL, Rao RV, Cottrell BA, Hayden MR, Ellerby LM, Bredesen DE. Double-stranded RNA-dependent protein kinase, PKR, binds preferentially to Huntington's disease (HD) transcripts and is activated in HD tissue. Hum Molec Genet. 2001; 10:1531–1538.
   PubMed Web of Science ®Google Scholar
• Bullido MJ, Martínez-García A, Tenorio R, Sastre I, Muñoz DG, Frank A, Valdivieso F. Double stranded RNA activated EIF2 alpha kinase (EIF2AK2; PKR) is associated with Alzheimer's disease. Neurobiol Aging. 2008; 29:1160–1166.
   Google Scholar
• Pachiappan A, Thwin MM, Manikandan J, Gopalakrishnakone P. Glial inflammation and neurodegeneration induced by candoxin, a novel neurotoxin from Bungarus candidus venom: global gene expression analysis using microarray. Toxicon. 2005; 46:883–899.
   PubMed Web of Science ®Google Scholar
• Martínez A, Santiago JL, Cénit MC, de Las Heras V, de la Calle H, Fernández-Arquero M, Arroyo R, de la Concha EG, Urcelay E. IFIH1-GCA-KCNH7 locus: influence on multiple sclerosis risk. Eur J Hum Genet. 2008; 16:861–864.
   PubMed Web of Science ®Google Scholar
• van den Berg TK, van Die I, de Lavalette CR, Döpp EA, Smit LD, van der Meide PH, Tilders FJ, Crocker PR, Dijkstra CD. Regulation of sialoadhesin expression on rat macrophages. Induction by glucocorticoids and enhancement by IFN-beta, IFN-gamma, IL-4, and lipopolysaccharide. J Immunol. 1996; 157:3130–3138.
   Google Scholar
• Micali OC, Cheung HH, Plenchette S, Hurley SL, Liston P, LaCasse EC, Korneluk RG. Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-β. BMC Cancer. 2007; 7:52.
   Google Scholar
• Perrelet D, Perrin FE, Liston P, Korneluk RG, MacKenzie A, Ferrer-Alcon M, Kato AC. Motoneuron resistance to apoptotic cell death in vivo correlates with the ratio between X–linked inhibitor of apoptosis proteins (XIAPs) and its inhibitor, XIAP-associated factor 1. J Neurosci. 2004; 24:3777–3785.
   Google Scholar